Proscia has partnered with Nucleai to integrate Nucleai’s AI-powered spatial biomarker solutions into Proscia’s Concentriq software platform, enhancing precision medicine capabilities for patient care. This collaboration aims to provide pathologists and clinicians with advanced tools to better utilize biopsy data for more effective clinical trial and treatment decisions.
“Together, Proscia and Nucleai will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions,” said Avi Veidman, Nucleai’s CEO. “Our partnership holds tremendous promise for advancing next-generation treatment modalities like ADCs, multispecifics, immunotherapy, and combination therapies. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale. Together with Proscia, we can fundamentally improve the efficiency and effectiveness of introducing groundbreaking treatments and advancing patient care.”
Discover more here.